CPAP therapy
DeviceCPAP treatment of obstructive sleep apnea with the excessively sleepy symptom subtype
NCT Number: NCT05742360
The primary objective of this study is to determine the longer-term (6 months) effect of CPAP therapy on change in 24-hour mean blood pressure (24hMBP) in OSA subjects with the excessively sleepy symptom subtype.
This study is active but is not currently recruiting participants.
Notify Me18 year–75 year
All sexes
Observational
The Ohio State University - Martha Morehouse Medical Pavilion, Suite 2600, Columbus, Ohio, United States
This is a prospective, non-randomized, observational, two-center study involving newly diagnosed subjects with moderate-severe OSA with the excessively sleepy symptom subtype.
Variables of Interest: Change in 24-hour ambulatory BP, change in sitting BP, change in reaction time by psychomotor vigilance test (PVT)
Participants will complete questionnaires that pertain to demographics, lifestyle factors, and co-morbidities. The blood samples will be used to determine levels of BP medications and serum creatinine. Measurements will be collected at baseline and at 6-month follow-up visits.
Data Analysis Approach: To correct for potential bias in the non-randomized comparison, the investigators will apply a Propensity Score (PS) Design via subclassification. Models to derive the PS values used in this design will include a number of covariates relevant to CPAP adherence, including age, sex, obesity (BMI, neck circumference, waist-to-hip ratio), current smoking, history of hypertension, diabetes mellitus (history, medications), lipid profile, hyperlipidemia (history, medications), family history of premature coronary disease, Charlson comorbidity index, physical activity (IPAQ), diet, OSA severity (AHI, ODI4, T90), sleepiness (Epworth Sleepiness Scale), educational attainment, socioeconomic status (postcode), insomnia symptoms (Insomnia Symptom Questionnaire), anxiety and depression-related symptoms (Patient Health Questionnaire-2), self-efficacy (General self-efficacy scale), and medication adherence (Medication Adherence Report Scale [MARS-5]). Baseline values of outcome measures will also be included in the PS model. After creating the PS design, all analyses are performed accounting for PS subclass as a categorical stratification factor. Evaluations of the CPAP effect on binary outcomes are performed utilizing conditional logistic regression. Similarly, CPAP effects in the context of survival analyses (e.g., Cox Proportional Hazards models) or on continuous outcomes (e.g., linear regression) are assessed by including PS subclass as a categorical covariate in all models.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
CPAP treatment of obstructive sleep apnea with the excessively sleepy symptom subtype
Time frame: Change from baseline 24-hour Mean Blood Pressure at 6-months after initiation of CPAP therapy
24-hour Mean Blood Pressure obtained from ambulatory blood pressure monitoring (ABPM)
Time frame: Change from baseline nocturnal Mean Blood Pressure at 6-months after initiation of CPAP therapy
Nocturnal Mean Blood Pressure obtained from ambulatory blood pressure monitoring (ABPM)
Time frame: Change from baseline reaction time at 6-months after initiation of CPAP therapy
Reciprocal of reaction time obtained by Psychomotor Vigilance Test
Ohio State University
Other
Effect of CPAP on 24-Hour Blood Pressure in the Excessively Sleepy Obstructive Sleep Apnea Subtype
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03361020
Apnea, Dyssomnias
Memphis, Tennessee, United States
View Trial DetailsNCT06053177
Apnea, Cardiovascular Diseases
Liverpool, United Kingdom
View Trial DetailsNCT06311045
Apnea, Dyssomnias
New York, United States
View Trial DetailsNCT03868618
Apnea, Dyssomnias
Birmingham, Alabama, United States
View Trial Details